---
title: "Pfizer Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains"
description: "Pfizer Inc. (PFE) shares rose 2.03% to $27.65 on Friday, despite a declining stock market, with the S&P 500 down 0.43% and the Dow Jones down 1.05%. This marks Pfizer's second consecutive day of gains"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277251080.md"
published_at: "2026-02-27T21:36:35.000Z"
---

# Pfizer Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

> Pfizer Inc. (PFE) shares rose 2.03% to $27.65 on Friday, despite a declining stock market, with the S&P 500 down 0.43% and the Dow Jones down 1.05%. This marks Pfizer's second consecutive day of gains, though it remains 1.04% below its 52-week high of $27.94. Compared to competitors, Pfizer's performance was mixed, as Johnson & Johnson, Eli Lilly, and Abbott Laboratories saw higher gains.

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Pfizer Inc. (PFE) rallied 2.03% to $27.65 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.43% to 6,878.88 and Dow Jones Industrial Average falling 1.05% to 48,977.92.

This was the stock's second consecutive day of gains.

Pfizer Inc. closed 1.04% short of its 52-week high of $27.94, which the company reached on February 13th.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 2.04% to $248.43, Eli Lilly & Co. (LLY) rose 2.93% to $1,051.99, and Abbott Laboratories (ABT) rose 0.08% to $116.35.

Data source: Dow Jones Market Data, FactSet. Data compiled February 27, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-27-26 1636ET

### Related Stocks

- [ABT.US - Abbott Laboratories](https://longbridge.com/en/quote/ABT.US.md)
- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 全球製藥公司加緊擴大在美國的存在，因為關税威脅迫在眉睫 | 全球製藥公司正在增加美國製造和庫存，以應對可能對進口藥品徵收 100% 的關税。輝瑞、禮來和強生等公司承諾投入數十億美元以擴大美國業務並降低供應鏈風險。輝瑞承諾投資 700 億美元，而禮來計劃在新工廠上投資 270 億美元。強生則計劃在四年 | [Link](https://longbridge.com/en/news/276628394.md) |
| 輝瑞及其他全球製藥巨頭正在大舉投資於中國減肥藥物的許可 | 全球製藥公司，包括輝瑞和阿斯利康，正在大力投資於中國減肥藥的許可，因為肥胖治療市場競爭激烈。輝瑞中國已同意支付高達 4.95 億美元以獲得 Sciwind Biosciences 開發的 GLP-1 藥物 ecnoglutide 的獨家權利 | [Link](https://longbridge.com/en/news/276889928.md) |
| BUZZ-街景：CagriSema 的 ‘難以恢復’ 形象對諾和諾德公司的長期前景構成打擊 | 丹麥製藥公司諾和諾德的 CagriSema 肥胖藥物在試驗中表現不及禮來的 Zepbound，導致其股價下跌 16% 並進一步虧損。分析師認為這對諾和諾德的長期前景是一個重大挫折，摩根大通表示 CagriSema 的前景 “難以恢復”。多家 | [Link](https://longbridge.com/en/news/276711872.md) |
| 諾和諾德明年大幅下調減肥神藥在美售價，降幅最高 50% | 諾和諾德宣佈將司美格魯肽系列藥物美國月標價統一降至 675 美元，降幅最高 50%，明年 1 月生效，旨在應對禮來競爭與市場壓力。消息公佈後美股盤前跌 3%，本週因新藥數據不佳已累跌 19%。降價主要惠及高免賠額計劃參保人，與 Medica | [Link](https://longbridge.com/en/news/276745048.md) |
| 輝瑞簽署了價值 4.95 億美元的協議，以獲得 Sciwind 減肥藥的使用權 | 輝瑞已簽署一項價值 4.95 億美元的協議，以獲得在中國獨家商業化權利，涉及由 Sciwind Biosciences 開發的減肥藥物 ecnoglutide。該協議旨在增強輝瑞在中國日益增長的減肥市場的影響力，當前肥胖症影響着 14.1% | [Link](https://longbridge.com/en/news/276734700.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.